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In this issue of Immunity, Spangler et al. and Mitra et al. demonstrate how structural changes in the IL-2
molecule alter interactions with the IL-2 receptor, leading to differential cellular targeting and biochemical
responses and selective immune consequences.Interleukin-2 (IL-2) is a four-helix bundle,
type I cytokine that functions as a growth
factor for a wide range of leukocytes. IL-2
was originally used therapeutically as an
immune stimulatory agent due to its ability
to enhance T effector (Teff) and NK cell
function (Smith 1988). Recombinant hu-
man IL-2 (Proleukin) was initially used at
high doses to treat metastatic melanoma
and renal cell carcinoma. However, only
a small subset of patients (5%–10%)
respond to such treatment, and adverse
effects of high-dose IL-2 therapy limit its
use (Rosenberg, 2014). In recent years, it
has become clear that IL-2 is a critical
cytokine for regulatory T (Treg) cell differ-
entiation, function, and survival. In fact,
the combination of genetic disruption
and IL-2 therapy studies led to the sur-
prising conclusion that IL-2 ismore impor-
tant in the control than in the promotion
of immune responses (Malek, 2008). IL-2
signaling and downstream gene activa-
tion of Treg cells occurs at lower IL-2
concentrations as compared to Teff or
natural killer (NK) cells. Capitalizing on
these observations, an increasing num-
ber of animal and human studies have
demonstrated that low doses of IL-2 can
preferentially expand Treg cells in vivo
and suppress graft-versus-host disease
(GVHD) and autoimmunity. As such, low-
dose IL-2 therapy represents a novel
approach to immune modulation for the
treatment of disease (Yu et al., 2015).
In 2006, Boyman and Sprent first re-
ported that IL-2 binding antibodies
(JES6-1 and S4B6 mAbs) could promote
the expansion of opposing cell types
in vivo. Much like low-dose IL-2 therapy,
JES6-1 promotes the expansion of Treg
cells, whereas a distinct antibody, S4B6,
preferentially expands effector T cells,
akin to high-dose IL-2 therapy (Boyman
et al., 2006). Subsequently, JES6-1 incomplex with IL-2 has been efficacious in
treating many mouse models of autoim-
mune disease and inflammation (Tang
et al., 2008). A major hypothesis put for-
ward to explain these results was that the
different mAb affinity and binding sites
lead to distinct half-lives of the IL-2, result-
ing in selective engagement and activation
of distinct T cell subsets. However, it re-
mained possible that the antibody binding
to IL-2 could induce a conformational
change that altered IL-2 binding to the IL-
2 receptor. In this regard, in 2012, theGar-
cia lab identified mutations in human IL-2
that stabilized certain IL-2 conformations
with higher binding affinity for IL-2Rb by
locking a flexible helixwithin IL-2’s binding
site for IL-2Rb. This IL-2 mutant, termed
‘‘super-2’’ or H9, proved to be 1–2 logs
morepotent in inducingpSTAT5activation
of cells lacking IL-2Ra than wild-type IL-2
(Levin et al., 2012). In this issue of Immu-
nity, two groups have interrogated the
consequences of alterations of IL-2 struc-
ture on T cell activation. In the paper by
Spangler et al. (2015), the investigators
demonstrated the key structural changes
induced by mAb binding to IL-2 that leads
to selective Treg or Teff cell induction, and
inMitra et al. (2015), the investigators used
mutational analysis of IL-2 to develop a
molecule that can act as a partial agonist
and/or antagonist to blunt immune re-
sponses. These two papers extend our
understanding of IL-2 signaling and the
potential to develop novel IL-2-based
therapeutics to treat diseases.
Central to understanding the seemingly
divergent activity of IL-2 is an understand-
ing of its interaction with the IL-2 receptor.
After antigen stimulation, surface expres-
sion of interleukin-2 receptor a chain (IL-
2Ra) sensitizes T cells to low concentra-
tions of IL-2 by capturing the cytokine
and presenting it first to IL-2Rb chain,Immunityand then the gc chain to form the IL-2R
trimeric complex. Treg cells express high
amounts of IL-2Ra constitutively. How-
ever, for some cell types, such as NK cells
and memory CD8+ T cells, IL-2Ra is virtu-
ally absent and signaling occurs predom-
inantly through the low-affinity IL-2Rb-gc
dimer; thus, stimulation requires much
higher levels of IL-2. The paper by Span-
gler et al. (2015) describes the detailed
molecular mechanism of action by which
two IL-2 binding antibodies, JES6-1 and
S4B6, exert their cell-targeted activity.
Spangler et al. (2015) solved the crystal
structure of JES6-1 in complex with
mouse IL-2 and observed that JES6-1
binds to IL-2 in a way that sterically blocks
binding of IL-2Rb and IL-2R-gc. Unex-
pectedly, binding of JES6-1 also induces
an allosteric change in the portion of IL-2
that binds IL-2Ra, resulting in an overall
reduced binding affinity for IL-2Ra. Thus,
only cells with high levels of IL-2Ra,
such as Treg cells, can bind the JES6-
1:IL-2 complex. The binding of IL-2:JES6
to IL-2Ra then prompts the dissociation
of JES6-1 from IL-2, permitting normal
signaling to occur. Cells stimulated with
JES6-1:IL-2 complexes also upregulate
IL-2Ra, lending an additional layer of
transcriptional regulation. In contrast, the
binding of S4B6 to IL-2 completely blocks
its interaction with IL-2Ra. However,
S4B6 binding induces a slight change in
the conformation of IL-2, resulting in
increased affinity for binding to IL-2Rb
and increased stability of the complex
bound to IL-2Rb. Effector cells with high
IL-2Rb expression are therefore favored
with S4B6:IL-2 complexes. The implica-
tions of these studies are significant: it
goes beyond previous hypotheses to
explain the divergent activities of the two
prototypic antibodies, by demonstrating
that conformation changes in the IL-242, May 19, 2015 ª2015 Elsevier Inc. 779
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Figure 1. Different Approaches to Change IL-2 Conformation to Alter Function
On the left side, binding of JES6-1 to IL-2 changes the conformation of the molecule resulting in reduced
IL-2Ra binding affinity. Only cells with high levels of IL-2Ra (such as Treg cells) can bind the JES6-1:IL-2
complex efficiently. The opposite function is elicited by S4B6, which increases IL-2 affinity for IL-2Rb, re-
sulting in effector T cell activation. The right side illustrates a different, mutational approach to generate
distinct IL-2 variants, which alters IL-2R-gc binding. The affinity of the interaction between these mutants
and the gc regulates signal intensity, generating IL-2 molecules that can more potently activate pSTAT5 or
completely block Treg cell differentiation and induce proliferation of pre-activated CD8+ T cells. Both of
these approaches generate IL-2 molecules that can function as agonists or antagonists depending on
cell type.
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Previewsmolecule alter its binding kinetics and
signaling properties favoring one cell
type over another (Spangler et al., 2015).
In the second paper in this issue, Mitra
et al. (2015) have exploited recent struc-
tural analyses of IL-2 to develop new
IL-2 variants to alter IL-2R signaling. Built
on the super-2 backbone, the investiga-
tors made additional mutations that alter
binding to IL-2R-gc, leading to a heterodi-
merization defect. By modulating the
severity of the defect, a series of IL-2 mol-
ecules was developed that function as
partial agonists, and even a functional
antagonist. Because of their increased
binding to IL-2Rb, these molecules
engage cells dominantly over endoge-
nous IL-2, and their levels of interaction
with the gc regulate signal intensity. As
proof of principle, Mitra et al. (2015)
showed that freshly isolated CD8+
T cells and pre-activated CD8+ T cells
have distinct activation thresholds for IL-
2 signaling, demonstrated by the differen-
tial effects of two muteins, H9-T and
H9-RET. The H9-T mutein more potently
activated STAT5 phosphorylation on acti-780 Immunity 42, May 19, 2015 ª2015 Elsevivated T cells than on naive cells. On the
other hand, H9-RET almost completely
blocked Treg cell differentiation and could
induce proliferation of pre-activated CD8+
T cells. Conversely, the mutein H9-RETR,
which is an extremely weak partial
agonist, was capable of inhibiting the ac-
tivity of wild-type IL-2. Mitra et al. (2015)
also showed that the ‘‘null’’ H9-RETR mu-
tein blocked IL-2Ra induction, prolonged
GVHD survival, and strongly inhibited the
spontaneous proliferation of adult T cell
leukemia cells. H9-RETR, which is spe-
cific for IL-2Rb but independent of IL-
2Ra, might offer a novel approach for
treatment of autoimmune diseases and
organ rejection, potentially even in combi-
nation with antibodies that block IL-2Ra
to disrupt the signaling of the high-affinity
IL-2 receptor (Mitra et al., 2015).
Cytokines and cytokine receptors have
long been recognized as intriguing targets
of therapeutic intervention. The therapeu-
tic conundrum lies in the fact that seem-
ingly opposing effects can be achieved
with the same molecule, as with IL-2 ther-
apy described above. Cytokine receptorer Inc.sub-unit expression varies on different
cell types, and receptor sub-units can
be shared by different cytokines, adding
to the complexity. To date, the relatively
blunt therapeutic approach of a neutral-
izing antibody or soluble receptor fusion
protein has left little room for finesse.
The approaches discussed here, of using
antibodies to bias cytokines to specific
cells or of manipulating the cytokine itself
to fine-tune the signaling outcome, pro-
vide new tools, which will allow for a
more nuanced understanding of cytokine
biology (Figure 1). However, it should be
noted that there might be additional impli-
cations of these alterations that could
lead to unexpected consequences. For
instance, recent studies have shown
that innate lymphoid cells 2 (ILC2s) ex-
press high amounts of IL-2Ra and are
activated by low-dose IL-2 in mouse
and humans, which can lead to eosino-
philia (Van Gool et al., 2014). Also, it re-
mains possible, as suggested by Bayer
et al. (2013), that IL-2 signaling is distinct
in different T cell subsets, and therefore,
simple alterations of IL-2 binding to the
IL-2R might not lead to predictable
changes of IL-2 function in vivo. Finally,
the studies discussed here suggest that
appropriate antibodies or muteins could
lead to partial IL-2R agonists that ‘‘tune’’
IL-2 signaling to induce desired functional
properties while avoiding thresholds for
undesired responses. Moreover, the re-
sults provide a road map to the develop-
ment of anti-human IL-2 antibodies that
can be developed to selectively promote
regulation or effector function depending
on the clinical setting. These efforts could
be extremely powerful in deepening our
understanding of the biological functions
of this pleiotropic cytokine, lead to
distinctive therapeutic benefits depend-
ing on the context, and provide a blue-
print from which to engineer analogous
molecules in other cytokine/cytokine re-
ceptor systems. Most importantly, it is
interesting to speculate that should such
IL-2 molecules or anti-IL-2:IL-2 com-
plexes be therapeutically viable, the po-
tential clinical applications might be
quite broad, perhaps even adaptable
to cancer and autoimmunity and also
to non-immune diseases such as Alz-
heimer’s, Parkinson’s, cardiac diseases,
or NASH, where chronic inflammation
has been shown to be pathogenic and im-
mune suppression via Treg cells to be
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Previewstherapeutic. Therefore, these studies vali-
date the adage that appearance is more
than skin deep and that structure can in-
fluence function.ACKNOWLEDGMENTS
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Using new rapid, super-resolution imaging methods, Ritter et al. (2015) define the early events of immuno-
logical synapse formation and granule release.A hallmark of the adaptive immune
response is T cell interaction with anti-
gen-presenting cells (APCs). An important
concept established over the last 10 years
is the discovery that during the process
of antigen recognition, membrane and
intracellular proteins become rearranged
in the contact area. This rearrangement
of molecules is now known as the immu-
nological synapse.
Applying fluorescence microscopy to
study the process of T cell activation was
the critical tool that allowed the synapse
to be discovered. Investigators deter-
mined the position ofmolecules in the syn-
apse by using antibodies to stain fixed T-
cell-APC conjugates or by imaging the
movement of fluorescent molecules
embedded in freely mobile lipid bilayers
(Bromley et al., 2001). However, these
types of approaches were limited by the
quality and diversity of available anti-
bodies and the availability of fluorescently
labeled purified membrane proteins
required for bilayer studies. The applica-tion of GFP and its derivatives enabled
molecules of interest to be directly labeled
and imaged in live cells. Later, the use of
total internal reflection fluorescence
(TIRF) microscopy, which excites a thin
100- to 200-nm layer of molecules in the
plasma membrane, markedly improved
the resolutionandallowed for single-mole-
cule tracking. However, the small size of
the synapse (between 8 and 10 mm in
diameter) and the 200- to 300-nm resolu-
tion of light microscopy still continue to
limit what can be seen. Fortunately, new
methods applied to imaging the synapse
continue to shed new light on the cell
biology of the immunological synapse.
In this issue, Ritter et al. (2015) used
a variety of cutting-edge methods,
including spinning-disk confocal micro-
scopy and lattice light-sheet microscopy,
to get an unparalleled look into the events
that underpin synapse formation and
granule secretion.
Conventional confocal microscopy
uses a laser to illuminate a single pointon the sample and rasters across to
generate the image. Because it takes sec-
onds to generate each optical section,
events that occur in the millisecond range
cannot be visualized via conventional
confocal microscopy. In addition, while
the image is being assembled point by
point, the laser strikes the complete thick-
ness of the specimen repeatedly but only
detects a single focal plane, leading to cell
toxicity and bleaching of the fluorophore.
Thus, the ‘‘efficiency’’ of excitation to
emission detection is quite low. However,
in spinning-disk confocal microscopy, the
excitation light is split through a disk with
multiple pinholes, allowing for several
points on the sample to be imaged at
the same time. This allows for high-speed
confocal imaging and reduced toxicity
because of decreased repeated illumina-
tion. In both methods, moving the focal
plane up and down allows a 3D image to
be obtained but also significantly in-
creases the amount of time required for
generating an image.42, May 19, 2015 ª2015 Elsevier Inc. 781
